PhaseBio Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

PhaseBio Pharmaceuticals

12/08/2021 15:34

* PhaseBio Pharmaceuticals Inc  PHAS.OQ  reported a quarterly
adjusted loss of 60 cents​​ per share for the quarter ended in
June. The mean expectation of four analysts for the quarter was
for a loss of 46 cents per share.
* Revenue was $10.34 million​;  analysts expected $5.02
million. 
* PhaseBio Pharmaceuticals Inc's reported EPS for the quarter
was a loss of 60 cents​.
* The mean earnings estimate of analysts had risen by
about 32.9% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* PhaseBio Pharmaceuticals Inc shares had fallen by 10.2% this
quarter and lost 0.6% so far this year.
* The company reported a quarterly loss of $28.68 million.
* Wall Street's median 12-month price target for PhaseBio
Pharmaceuticals Inc is $16.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 12 at 02:34 p.m.  ​All
figures in US dollars unless otherwise stated